Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19 genetic polymorphisms and proton pump inhibitor therapy resistance in patients with gastrooesophageal reflux disease: a preliminary observational cohort study.

Drug metabolism and personalized therapy - 1 Mar 2026

DeBattista Jamie-Lee, Zahra Graziella, Barbara Christopher, Schembri John, Azzopardi Lilian M, Wirth Francesca

Abstract excerpt

OBJECTIVES: Clinical relevance of CYP2C19 genetic polymorphisms in real-world patient populations requires further investigation. This study aimed to determine the prevalence of CYP2C19 genetic variants in patients with GORD showing resistance to PPI therapy and possible clinical implications. METHODS: Patients with GORD and documented PPI resistance were identified from ambulatory reflux monitoring and endoscopy...

Topics

Humans
Cytochrome P-450 CYP2C19
Male
Proton Pump Inhibitors
Gastroesophageal Reflux
Middle Aged
Female
Drug Resistance
Polymorphism, Genetic
Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Genotype

Adult

Source

Identifiers

PMID: 41762662
DOI: 10.1515/dmpt-2025-0077

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19 genetic polymorphisms and proton pump inhibitor therapy resistance in patients with gastrooesophageal reflux disease: a preliminary observational cohort study.PMID 41762662Read ↗

Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.Semantic proximity Read ↗

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.Semantic proximity Read ↗

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.Semantic proximity Read ↗

High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease.Semantic proximity Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Semantic proximity Read ↗

Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.Semantic proximity Read ↗

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Semantic proximity Read ↗

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitorsSemantic proximity Read ↗

Association of CYP2C19 Phenotype on Historical Medication Prescribing for Gastroesophageal Reflux Disease.Semantic proximity Read ↗

Prevalence of CYP2C19 phenotypes in patients undergoing a hiatal hernia repair.Semantic proximity Read ↗

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.